Volume 30, Issue 10 (January 2019)                   Studies in Medical Sciences 2019, 30(10): 819-830 | Back to browse issues page

XML Persian Abstract Print

Professor, Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran (Corresponding Author) , dehghan2001d@yahoo.com
Abstract:   (2583 Views)
Background & Aims: Breast cancer is a threatening disease in females and is the second common cancer among women after lung cancer. The aim of this research is to bioinformatically and experimentally evaluate the effect of methotrexate (MTX) on the expression of HMGA2 and SMARCA5 genes in the MTX treated 4T1 cancer cell line.
Materials & Methods: To perform this study, initially microarray data were collected from Gene Expression Omnibus (GEO) then they were analyzed using Probabilistic neural networks (PNN) in MATLAB 2018a software as a bioinformatics tool. In the next step, the specific primers were designed for HMGA2 and SMARCA5 genes. MTX cytotoxicity was assessed on 4T1 cancer cells using MTT assay. Finally, Real-time PCR was used for evaluating the effect of MTX on the rate of HMGA2 and SMARCA5 genes expression.
Results: The bioinformatic analysis showed that HMGA2 and SMARCA5 expression levels notably reduced and increased respectively in MTX treated group in comparison with the control (untreated) group. MTT assay indicated that MTX decreased the 4T1 cell viability in a concentration-dependent manner and the IC50 value of MTX was estimated to be 208 µg/ml in 48 hours. Real-time PCR data showed that the expression level of HMGA2 decreased significantly (p ≤ 0.05), while the SMARCA5 gene was significantly (p ≤ 0.05) upregulated which is consistent with bioinformatic analysis results.
Conclusion: The obtained results suggest that HMGA2 and SMARCA5 genes may be used as MTX target genes in breast cancer therapy. However, further studies need to be carried outto confirm the results.
Full-Text [PDF 890 kb]   (1421 Downloads)    
Type of Study: Research | Subject: داروسازی

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.